NASDAQ · NTRBW
Healthcare · Biotechnology
$1.44
Up+$0.00 (+0.00%)
Updated Sep 20, 2026, 11:52 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
NTRBW does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning NTRBW.
NTRBW research
Company profile and research snapshot.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Feb 17, 2026
Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products
defenseworld.net · Dec 5, 2025
Nutriband Inc. (NASDAQ: NTRBW - Get Free Report)'s stock price traded down 5% during mid-day trading on Thursday. The company traded as low as $0.80 and last traded at $1.33. 210 shares changed hands during trading, a decline of 97% from the average session volume of 6,697 shares. The stock had previously closed at $1.40.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NTRBW.
No results
No recent SID articles mention NTRBW.
